Takeshi Yoroidaka

Kanazawa, 9208641, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL.

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL.

Journal: International journal of hematology

Published: April 21, 2026

Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses.

Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses.

Journal: Haematologica

Published: March 09, 2026

Clinical implications of minimal residual disease monitoring in multiple myeloma.

Clinical implications of minimal residual disease monitoring in multiple myeloma.

Journal: International journal of hematology

Published: December 05, 2025

Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.

Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.

Journal: International journal of hematology

Published: June 18, 2025

Cryopreservation of haematopoietic stem cells using a zwitterion.

Cryopreservation of haematopoietic stem cells using a zwitterion.

Journal: Philosophical transactions. Series A, Mathematical, physical, and engineering sciences

Published: May 30, 2025

Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.

Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.

Journal: International journal of hematology

Published: January 23, 2025

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study.

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study.

Journal: Haematologica

Published: January 22, 2025

3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients with Multiple Myeloma using Whole-body MRI.

3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients with Multiple Myeloma using Whole-body MRI.

Journal: Journal of medical systems

Published: May 25, 2023

Familial immune-mediated aplastic anaemia in six different families.

Familial immune-mediated aplastic anaemia in six different families.

Journal: EJHaem

Published: January 28, 2023

Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.

Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.

Journal: EJHaem

Published: November 30, 2022

Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.

Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.

Journal: Anticancer research

Published: October 21, 2022

Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4.

Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4.

Journal: EJHaem

Published: May 13, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026